New Member Introduction | AstraZeneca China

AstraZeneca entered China in 1993. In line with the “patient-centric” value, we advance the  innovation in research and development, operation and commercialization to help Chinese patients with unmet healthcare needs, so as to drive business growth in China and realize sustainable  development, fulfilling our grand mission of “becoming China’s most trusted healthcare partner by bringing forth innovative solutions to improve the lives of Chinese patients”.

AstraZeneca’s China headquarters are located in Shanghai, with regional headquarters in Beijing, Guangzhou, Wuxi, Hangzhou and Chengdu. The company has over 18,000 employees throughout the country, and achieved sales of nearly USD4.9 billion in 2019. AstraZeneca’s investment in R&D in China has reached USD1.5 billion, with another investment of more than USD1 billion in manufacturing and operation sites. We have introduced nearly 35 innovative medicines covering respiratory, cardiovascular, metabolic,oncology,gastrointestinal and renal diseases to China, and have built supply sites in Wuxi and Taizhou, as well as the China Distribution Center in Wuxi. AstraZeneca has exported high-quality innovative medicines to nearly 80 countries and regions around the world.

To accelerate scientific innovation in China, AstraZeneca continues to invest in and build up an R&D platform fully dedicated to the Chinese market. We focus on every stage of the drug lifecycle and enhance our scientific innovation capability across the pharmaceutical industry. In 2015, AstraZeneca established the R&D China team. In 2017, AstraZeneca and State Development & Investment Corp., Ltd. (SDIC) Fund jointly established Dizal Pharmaceutical to accelerate local development of innovative medicines. In 2019, AstraZeneca announced to upgrade its Shanghai R&D platform to a global R&D center. Currently, AstraZeneca is promoting the development of ten Chinese original medicines. Combined with in-house R&D and external collaborations, we are speeding up the process to bring innovative medicines to patients in China and worldwide.

Adhering to our initial goal of being “patient-centric”, AstraZeneca proactively responds to the government’s call for “innovation-driven development” by putting forward and practicing the “China Commercial Innovation Strategy”, which continuously gathers innovative forces at home and abroad to create a diversified innovative healthcare ecosystem. With our strong expertise and market advantages in key therapy areas in China, AstraZeneca launched the China Healthcare IoT Innovation Center in 2017 to demonstrate the 14 end-to-end holistic disease management solutions designed based on the healthcare needs of Chinese patients.The solutions have been launched in hospitals nationwide, with some launched in many other countries around the world as well. In 2019, AstraZeneca announced to co-build the Wuxi International Life Science Innovation Park with the Wuxi municipal government and Wuxi Hi-tech District. With access to the global network of  AstraZeneca, the new incubation and innovation platform will cover the entire cycle of life science  and holistic disease management process, benefiting companies in fields of pharmaceuticals, diagnostics, instruments, and digitization. At the same year, AstraZeneca also announced to establish an AI Innovation Center in Shanghai, as well as joined hands with CICC Capital to establish a global Healthcare Industrial Fund, which is expected to raise up to US $1 billion in the future.

The innovative government-enterprise partnership is the foundation of AstraZeneca’s integration and innovation efforts. Through close interaction with domestic and overseas government, AstraZeneca is actively promoting industrial reform and development, continuously bringing global wisdom and strength to benefit Chinese patients, and introducing “China’s Innovation” to the world to fulfill our commitment of “in China, for China and the world”.

Talent cultivation is the cornerstone of AstraZeneca’s long-term development in China. We are committed to cultivating local innovative talents with international perspectives. Through the  Plan100 project, we realize the exchange of domestic and overseas talents, providing unlimited possibilities for the diversification and sustainable development of talents.

Furthermore, AstraZeneca China has proactively fulfilled its social responsibilities through close  collaboration with stakeholders to support various programs including patient assistance, accurate  poverty alleviation, grassroots assistance, charity and disaster relief, youth care, and science communication, striving to be a respected corporate citizen recognized by multiple stakeholders.